Pattern of liver function and clinical profile in COVID-19 : A cross-sectional study of 91 patients
Copyright © 2020 Diabetes India. Published by Elsevier Ltd. All rights reserved..
BACKGROUND: - COVID-19 caused by SARS-CoV-2 leads to myriad range of organ involvement including liver dysfunction.
AIM: To analyse the liver function in patients with COVID-19 and their association with respect to age, sex, severity of disease and clinical features.
MATERIALS AND METHODS: This study was a cross-sectional study done at Rajendra Institute of Medical Sciences, Ranchi. 91 patients admitted with confirmed SARS-CoV-2 infection were included in this study and divided into asymptomatic, mild, moderate and severe groups. Liver function tests were compared among different severity groups.
RESULTS: Of 91 patients with COVID-19, 70 (76.9%) had abnormal liver function. Aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP), total bilirubin levels was 1-2 × ULN in 33(36.3%), 34(37.3%), 12(13.2%), 6(6.6%) cases and >2 × ULN in 20(22%), 18(19.8%), 7(7.7%) and 2 (2.2%) cases respectively. Mean AST and ALP levels among different severity groups of COVID-19 was statistically significant (p < 0.05) whereas mean ALT and total bilirubin levels was statistically non-significant (p > 0.05). There was no statistical difference between males and females with regard to abnormal liver function. Liver injury was seen in 64.3% cases of hypertension and 73.3% cases of diabetes. Fever, myalgia, headache and breathlessness were found to be correlated significantly with severity of disease.
CONCLUSION: Liver injury is common in SARS-CoV-2 infection and is more prevalent in the severe disease group. Aspartate transaminase and alkaline phosphatase are better indicators of covid-19 induced liver injury than alanine transaminase and total bilirubin.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Diabetes & metabolic syndrome - 14(2020), 6 vom: 22. Nov., Seite 1951-1954 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kumar, Abhishek [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Alanine Transaminase |
|---|
| Anmerkungen: |
Date Completed 08.01.2021 Date Revised 10.01.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.dsx.2020.10.001 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM316098388 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM316098388 | ||
| 003 | DE-627 | ||
| 005 | 20231225160339.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.dsx.2020.10.001 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1053.xml |
| 035 | |a (DE-627)NLM316098388 | ||
| 035 | |a (NLM)33039937 | ||
| 035 | |a (PII)S1871-4021(20)30389-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kumar, Abhishek |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pattern of liver function and clinical profile in COVID-19 |b A cross-sectional study of 91 patients |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.01.2021 | ||
| 500 | |a Date Revised 10.01.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Diabetes India. Published by Elsevier Ltd. All rights reserved. | ||
| 520 | |a BACKGROUND: - COVID-19 caused by SARS-CoV-2 leads to myriad range of organ involvement including liver dysfunction | ||
| 520 | |a AIM: To analyse the liver function in patients with COVID-19 and their association with respect to age, sex, severity of disease and clinical features | ||
| 520 | |a MATERIALS AND METHODS: This study was a cross-sectional study done at Rajendra Institute of Medical Sciences, Ranchi. 91 patients admitted with confirmed SARS-CoV-2 infection were included in this study and divided into asymptomatic, mild, moderate and severe groups. Liver function tests were compared among different severity groups | ||
| 520 | |a RESULTS: Of 91 patients with COVID-19, 70 (76.9%) had abnormal liver function. Aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP), total bilirubin levels was 1-2 × ULN in 33(36.3%), 34(37.3%), 12(13.2%), 6(6.6%) cases and >2 × ULN in 20(22%), 18(19.8%), 7(7.7%) and 2 (2.2%) cases respectively. Mean AST and ALP levels among different severity groups of COVID-19 was statistically significant (p < 0.05) whereas mean ALT and total bilirubin levels was statistically non-significant (p > 0.05). There was no statistical difference between males and females with regard to abnormal liver function. Liver injury was seen in 64.3% cases of hypertension and 73.3% cases of diabetes. Fever, myalgia, headache and breathlessness were found to be correlated significantly with severity of disease | ||
| 520 | |a CONCLUSION: Liver injury is common in SARS-CoV-2 infection and is more prevalent in the severe disease group. Aspartate transaminase and alkaline phosphatase are better indicators of covid-19 induced liver injury than alanine transaminase and total bilirubin | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Clinical profile | |
| 650 | 4 | |a Liver dysfunction | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 7 | |a Aspartate Aminotransferases |2 NLM | |
| 650 | 7 | |a EC 2.6.1.1 |2 NLM | |
| 650 | 7 | |a Alanine Transaminase |2 NLM | |
| 650 | 7 | |a EC 2.6.1.2 |2 NLM | |
| 650 | 7 | |a Alkaline Phosphatase |2 NLM | |
| 650 | 7 | |a EC 3.1.3.1 |2 NLM | |
| 650 | 7 | |a Bilirubin |2 NLM | |
| 650 | 7 | |a RFM9X3LJ49 |2 NLM | |
| 700 | 1 | |a Kumar, Piyush |e verfasserin |4 aut | |
| 700 | 1 | |a Dungdung, Ajit |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar Gupta, Anitesh |e verfasserin |4 aut | |
| 700 | 1 | |a Anurag, Aditya |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Abhinav |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Diabetes & metabolic syndrome |d 2007 |g 14(2020), 6 vom: 22. Nov., Seite 1951-1954 |w (DE-627)NLM189445564 |x 1878-0334 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2020 |g number:6 |g day:22 |g month:11 |g pages:1951-1954 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.dsx.2020.10.001 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2020 |e 6 |b 22 |c 11 |h 1951-1954 | ||